
Clinical Trials - January 22, 2015
Astra’s Brilinta Gets a Boost
On the heels of positive outcomes from a second study of the blood thinner Brilinta, AstraZeneca plans to use the results to bolster an application to the U.S. Food and Drug Administration (FDA) to expand and extend the use of the anti-platelet drug. Called the Pegasus study, it followed 21,000 patients who’d had heart attacks and found that long-term use of Brilinta in […]